ZIVO vs. AIM, EVAX, APTO, SNTI, PMCB, CRTX, TVGN, BCLI, PLUR, and NKGN
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include AIM ImmunoTech (AIM), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Senti Biosciences (SNTI), PharmaCyte Biotech (PMCB), Cortexyme (CRTX), Tevogen Bio (TVGN), Brainstorm Cell Therapeutics (BCLI), Pluri (PLUR), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.
ZIVO Bioscience (NASDAQ:ZIVO) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, community ranking, media sentiment, institutional ownership and valuation.
ZIVO Bioscience has a net margin of -11,068.75% compared to AIM ImmunoTech's net margin of -14,337.62%. ZIVO Bioscience's return on equity of 0.00% beat AIM ImmunoTech's return on equity.
ZIVO Bioscience received 43 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 61.11% of users gave ZIVO Bioscience an outperform vote.
ZIVO Bioscience has higher earnings, but lower revenue than AIM ImmunoTech. ZIVO Bioscience is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 13.4% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
ZIVO Bioscience has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.
In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 2 articles in the media. ZIVO Bioscience's average media sentiment score of 1.38 beat AIM ImmunoTech's score of 0.96 indicating that ZIVO Bioscience is being referred to more favorably in the media.
Summary
ZIVO Bioscience beats AIM ImmunoTech on 9 of the 14 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
